Are the real‐life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?

2018 ◽  
Vol 97 (2) ◽  
Author(s):  
Aisling K. Higham ◽  
Muhammad I. Tahir ◽  
Kavita Gala ◽  
Georgios Verroiopoulos
Keyword(s):  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Life Outcomes ◽  
The Real

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

2020 ◽  
pp. 112067212092727
Author(s):  
Marko Lukic ◽  
Gwyn Williams ◽  
Zaid Shalchi ◽  
Praveen J Patel ◽  
Philip G Hykin ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Early Treatment ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Macular Volume ◽  
Central Foveal Thickness ◽  
The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD

2021 ◽  
pp. 112067212110523
Author(s):  
Martin Stattin ◽  
Anna-Maria Haas ◽  
Daniel Ahmed ◽  
Alexandra Graf ◽  
Katharina Krepler ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Real Life ◽  
Treatment Interruption ◽  
Term Treatment ◽  
Calculation Model ◽  
Life Outcomes ◽  
Short Term ◽  
Short Term Treatment ◽  
The Real ◽  
The Impact

Purpose A model was calculated during the first Austrian coronavirus disease-2019 (COVID-19) pandemic lockdown to estimate the effect of a short-term treatment interruption due to healthcare restrictions on visual acuity (VA) in neovascular age-related macular degeneration (nAMD). The model was compared to the real-life outcomes before treatment re-started. Methods Retrospective data-collection of 142 eyes in 142 patients receiving repeated intravitreal injections with anti-VEGF at a retina unit in Vienna in a personalized pro-re-nata regimen prior to the COVID-19 associated lockdown, when treatment was deferred between March 16 and May 4, 2020. During the lockdown, the preliminary data was integrated into pre-existing formulae based on the natural course of the disease in untreated eyes in the long term. Patients were re-scheduled and treated after gradually opening operating rooms. The calculation model was compared to the effective VA change. Results The model calculated an overall VA loss of 3.5 ± 0.8 letters early treatment diabetes retinopathy study (ETDRS) ( p < 0.001 [95% CI:3.3;3.6]) on average compared to 2.5 ± 6 letters ETDRS ( p < 0.001 [95% CI:1.5;3.5]) as measured with a mean treatment delay of 61 ± 14 days after previously scheduled appointments. The total difference between the model exercise and the real-life outcomes accounted for 1 ± 5.9 letters ETDRS ( p = 0.051 [95% CI: 0.1;1.9]). Conclusion The herein presented calculation model might not be suitable to estimate the effective VA loss correctly over time, although untreated eyes and eyes under therapy show similarities after short-term treatment interruption. However, this study demonstrated the potentially negative impact of the COVID-19 pandemic lockdown on patients compromised by nAMD.

scholarly journals Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

2019 ◽  
Vol Volume 13 ◽  
pp. 2583-2590
Author(s):  
Tommi Karttunen ◽  
Lasse Nummelin ◽  
Kai Kaarniranta ◽  
Kati Kinnunen
Keyword(s):  
Macular Oedema ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

The real life outcomes of modified docetaxel and cisplatin plus fluorourasil regimen in patients with metastatic gastric cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15548-e15548
Author(s):  
Tulay Eren ◽  
Nuriye Ozdemir Yildirim ◽  
Ozan Yazici ◽  
Goksen Inanc Imamoglu ◽  
Dogan Yazilitas ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real Life ◽  
Metastatic Gastric Cancer ◽  
Life Outcomes ◽  
The Real

scholarly journals An open-source dataset of anti-VEGF therapy in diabetic macular oedema patients over four years & their visual outcomes

2019 ◽  
Author(s):  
Christoph Kern ◽  
Dun Jack Fu ◽  
Josef Huemer ◽  
Livia Faes ◽  
Siegfried K. Wagner ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Cohort Study ◽  
Open Source ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Data Repository ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Observation Period

ABSTRACTPURPOSETo evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO).METHODSIn this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections (IVI) in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of visual acuity outcomes were reported for all eyes over a 4-year observation period.RESULTSOur cohort includes 2616 DMO eyes of 1965 patients over 48 months. Cox proportional hazards modelling identified injection number (hazard ratio [HR] = 1.18), male gender (HR = 1.13), and baseline VA (HR = 1.09) as independent predictors to reach a favorable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 by 14.7 months.CONCLUSIONTo date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our dataset available on an open-source data repository as a resource for all clinical researchers globally.SYNOPSISUsing time-to-event analysis in patients receiving anti-VEGF for DMO: age, baseline visual acuity and injection number are independent predictors of visual outcomes.

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

2018 ◽  
Vol 241 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Cláudia Farinha ◽  
Amélia Martins ◽  
Arminda Neves ◽  
Raquel Soares ◽  
Miguel Ruão ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Real World ◽  
Clinical Setting ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
The Real

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

2021 ◽  
pp. bjophthalmol-2021-319587
Author(s):  
Simon KH Szeto ◽  
Vivian W. K. Hui ◽  
Fang Yao Tang ◽  
Dawei Yang ◽  
Zi han Sun ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Serous Retinal Detachment ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Cystoid Macular Oedema ◽  
Anti Vegf ◽  
Central Subfield Thickness ◽  
Endothelial Growth Factors ◽  
Treatment Improvement ◽  
Sd Oct

Background/aimsTo determine whether a combination of baseline and change in spectral domain-optical coherence tomography (SD-OCT)-based biomarkers can predict visual outcomes in eyes with diabetic macular oedema (DMO) treated with antivascular endothelial growth factors (VEGF) injections.MethodsThis is a retrospective cohort study conducted in Hong Kong, China. 196 eyes with centre-involving DMO, who received anti-VEGF injections between 1 January 2011 and 30 June 2018 were recruited. Medical records of the participants were retrieved retrospectively, visual acuity (VA) at baseline, 6, 12 and 24 months and SD-OCT before initiation and after completion of anti-VEGF treatment were obtained. The SD-OCT images were evaluated for the morphology of DMO, vitreomacular status, presence of disorganisation of retinal inner layers (DRIL), sizes of intraretinal cysts, visibility of external limiting membrane (ELM), ellipsoid zone (EZ) and cone outer segment tip (COST) and the presence of hyper-reflective foci in retina or the choroid.ResultsThe presence of baseline DRIL, hyper-reflective foci in retina and disruption of ELM/EZ and COST were associated with worse baseline and subsequent VA up to 24 months after treatment. Improvement in DRIL (p=0.048), ELM/EZ (p=0.001) and COST (p=0.002) disruption after treatment was associated with greater improvement in VA at 12 months. Eyes with cystoid macular oedema (p=0.003, OR=8.18) and serous retinal detachment (p=0.011, OR=4.84) morphology were more likely to achieve at least 20% reduction in central subfield thickness.Conclusion and relevanceBaseline SD-OCT biomarkers and their subsequent change predict VA and improvement in vision in eyes with DMO treated with anti-VEGF injections. We proposed an SD-OCT-based system that can be readily used in real-life eye clinics to improve decision making in the management of DMO.

Sign in / Sign up

Export Citation Format

Share Document